<DOC>
	<DOCNO>NCT01527448</DOCNO>
	<brief_summary>This 9-week single-centre , open-label , dose-escalating study evaluate efficacy safety Quetiapine XR give monotherapy treatment non-lactating , post-partum woman diagnose Bipolar II Disorder . Subjects need visit study doctor 8 time period 9 week . During study period , subject receive treatment Quetiapine XR . The start dose quetiapine subject receive 50mg . The response treatment quetiapine determine whether study doctor increase dosage subject 's quetiapine . If study doctor increase quetiapine study , maximum dosage allowable study 300mg .</brief_summary>
	<brief_title>Quetiapine Treatment Postpartum Depression ( PPD ) Bipolar Disorder ( BD ) , Type II</brief_title>
	<detailed_description>This study help clinician increase awareness existence Bipolar II Disorder perinatal population provide guidance term appropriate treatment . Since diagnosis postpartum population do elimination , study provide evidence merit identify treat order time . When selective serotonin reuptake inhibitor ( SSRIs ) fail symptom relief woman diagnose unipolar depression , postpartum onset , clinician tend either augment combine variety psychotropic medication treatment response . It probably likely patient Bipolar II Disorder continue cycle treatment . Adding atypical antipsychotic often afterthought . Therefore , unique aspect treat specific population right outset diagnosis mood disorder make optimal . Clinicians need actively consider bipolar type II differential diagnosis , also initiate treatment soon possible relieve suffering . This study help diagnose postpartum Bipolar II Disorder test unique action quetiapine mood stabilize antidepressant property . Hypothesis : Quetiapine XR effective treatment postpartum depression woman Bipolar II Disorder .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depression , Postpartum</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>sign informed consent ; woman , 19 40 year ; meet Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criteria Bipolar II Disorder ( confirm Mini International Neuropsychiatric Interview ( MINI ) ) ; Hamilton Depression Rating Scale ( HAMD ) ( 17item ) total score &gt; 22 HAMD item 1 ( depressed mood ) score &gt; 2 Visit 1 ( enrolment ) &amp; Visit 2 ; negative serum pregnancy test enrolment , use reliable method birth control ( i.e . barrier method , oral contraceptive , implant , dermal contraception , longterm injectable contraceptive , intrauterine device , tubal ligation ) study ; understand comply requirement study outpatient status enrolment . DSMIV Axis I disorder Bipolar II Disorder within 6 month enrolment ; diagnosis DSMIV Axis II disorder major impact patient 's current psychiatric status ; substance alcohol abuse dependence within 6 month prior enrolment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion ; Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within 4 week prior enrolment ; use drug induce inhibit hepatic metabolizing cytochrome P450 3A4 enzyme within 2 week prior Visit 2 ; pregnancy lactation ; evidence clinically relevant disease , e.g. , renal hepatic impairment , significant coronary artery disease , cerebrovascular disease , viral hepatitis B C , acquire immunodeficiency syndrome ( AIDS ) ; clinical finding unstable inadequately treat , ( e.g. , hypertension , poorly control diabetes , unstable angina ) would negatively affect study medication affect study medication ; medical condition would affect absorption , distribution , metabolism , excretion study medication ( e.g. , malabsorption syndrome , liver disease ) ; current diagnosis cancer ( except basal squamous cell skin carcinoma ) unless remission least 5 year ; current past diagnosis stroke Transient Ischemic Attacks ( TIA ) ; history seizure disorder , except febrile convulsion ; receipt electroconvulsive therapy ( ECT ) within 90 day prior Visit 2 ; use antipsychotic , mood stabilizer , antidepressant drug within 7 day Visit 2 , use fluoxetine within 28 day Visit 2 , use monoamine oxidase inhibitor ( MAOIs ) , anxiolytic hypnotic within 14 day Visit 2 ( exception allow restriction per protocol ) , use depot antipsychotic injection within 2 dose interval Visit 2 ; subject require psychotherapy ( supportive psychotherapy ) study period , unless psychotherapy ongoing minimum 3 month prior Visit 2 ; subject pose current serious suicidal homicidal risk , HAMD item 3 score 3 great , make suicide attempt within past 6 month ; patient Diabetes Mellitus ( DM ) fulfil specific criterion judge investigator would make unable participate ; clinically significant deviation reference range clinical laboratory test result judge investigator ; absolute neutrophil count ( ANC ) &lt; 1.5 x 109 per liter ; thyroidstimulating hormone ( TSH ) concentration 10 % upper limit normal range laboratory use sample analysis enrolment , whether patient treat hypothyroidism ; liver function test aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) three time upper normal limit ; Electrocardiogram ( ECG ) result consider clinically significant base assessment centrally locate experienced cardiologist interpret ECG ; use quetiapine dose great 25mg/day insomnia within 7 day Visit 2 ; know history intolerance hypersensitivity quetiapine ; know lack response quetiapine treatment depression dosage least 50 mg per day 4 week ( time study start ) ; treatment quetiapine dosage least 50 mg/day Visit 1 ( enrolment ) ; contraindication detail countryspecific prescribe information quetiapine ; involvement planning conduct study ; previous enrolment AstraZenecasponsored study quetiapine ; participation another clinical study compassionate use programme within 4 week Visit 2 long accordance local requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>postpartum</keyword>
	<keyword>postpartum depression</keyword>
	<keyword>PPD</keyword>
	<keyword>quetiapine XR</keyword>
	<keyword>quetiapine</keyword>
	<keyword>seroquel</keyword>
	<keyword>bipolar</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>bipolar disorder , type II</keyword>
</DOC>